Mains Guidance Program (MGP) for UPSC CSE 2026, Cohort-1 starts 11th February 2025. Registrations Open Click Here to know more and registration.
News: The United States Food and Drug Administration (FDA) has approved Suzetrigine, a new non-opioid painkiller.
About Suzetrigine
- Suzetrigine is a non-opioid painkiller developed by US-based Vertex Pharmaceuticals.
- Unlike opioids, which work in the brain, suzetrigine blocks pain signals before they reach the brain.
- It targets nociceptors (specialized nerve endings that sense pain). This prevents the brain from perceiving pain despite the presence of tissue injury.
- Since it does not stimulate opioid receptors, it does not cause euphoria or addiction.
Significance of Suzetrigine
- Non-addictive alternative to opioids, addressing the opioid crisis in the US.
- Potential to reduce opioid dependency among pain patients.
- Can help prevent opioid overdose deaths, which reached 82,000 in 2022.
- Targets post-surgical pain and other moderate-to-severe pain conditions.
About Opioids
- Definition: Opioids are drugs that either derive from or mimic substances found in the opium poppy plant.
- Common Opioids: Morphine, oxycodone, codeine, fentanyl, and heroin.
- How They Work: They bind to opioid receptors in brain cells, blocking pain signals and creating feelings of pleasure or euphoria.
- Addiction Risk: While effective for pain relief, opioids can be highly addictive, leading to dependence and misuse.
Discover more from Free UPSC IAS Preparation Syllabus and Materials For Aspirants
Subscribe to get the latest posts sent to your email.
